Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for participants in the FLAIR and ATLAS-2M global Phase 3/3b studies through Week 96 stratified by race. Dr Ramgopal discusses the efficacy and safety findings from the phase 3/3b studies, the objectives of the post-hoc analysis, and the findings in terms of safety and treatment satisfaction.
The abstract entitled: ‘Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race‘ was presented at IDWeek 2022, 19-23 October 2022.
Questions:
- What did the FLAIR and ATLAS-2M teach us about the efficacy and safety of long-acting cabotegravir and rilpivirine in this treatment setting? (0:08)
- What was the objective of the post-hoc analysis you are presenting? (1:07)
- What were the findings in terms of safety and treatment satisfaction? (4:20)
Disclosures: Moti Ramgopal is a consultant for Merck, ViiV, and Gilead; and is a speaker’s bureau participant with Abbvie, Gilead, ViiV, and Janssen.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
